Federal regulators have begun a safety review of 2 RSV medicines used to protect infants, even though no safety problems have been reported.

U.S. regulators launch new review of infant RSV therapies from Merck, Sanofi, and AstraZeneca amid scrutiny by Health Secretary Robert F. Kennedy Jr.

Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

Federal officials say the U.S. Food and Drug Administration (FDA) is reviewing reports of possible deaths in adults and ...

On the campaign trail last October, President Trump promised to let his health secretary, Robert F. Kennedy Jr., “go wild on ...

FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...

The drugs are essentially laboratory-made versions of natural antibodies that help the immune system fight off RSV. The FDA ...

The FDA has informed Merck, Sanofi and AstraZeneca of the safety investigation into their RSV antibodies, though it remains ...

Over the past year, some vaccine recommendations have changed. Respiratory virus season is upon the United States as the cold weather months set in, meaning cases of COVID-19, influenza and RSV are ...

Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season If approved by the European ...

ENFLONSIA is Merck’s FDA-approved, extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower respiratory tract ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for the prevention of ...